United Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1996-01-01
- Employees
- -
- Market Cap
- $15.5B
- Website
- http://www.unither.com
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 1000
- Registration Number
- NCT06388421
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- Conditions
- Interventions
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 698
- Registration Number
- NCT05943535
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
🇺🇸UAB Lung Health Center, Birmingham, Alabama, United States
🇺🇸Norton Thoracic Institute, Phoenix, Arizona, United States
Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection
- Conditions
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 200
- Registration Number
- NCT05776225
- Locations
- 🇺🇸
Pulmonary Associates, Phoenix, Arizona, United States
🇺🇸Hartford Hospital, Hartford, Connecticut, United States
🇺🇸Lakeland Regional Health, Lakeland, Florida, United States
Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 597
- Registration Number
- NCT05255991
- Locations
- 🇧🇪
Ziekenhuis Aan de Stroom, Antwerpen, Belgium
🇦🇷CINME S.A. - Centro de Investigaciones Metabolicas, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
🇦🇷Centro Medico Dra. De Salvo, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
- Conditions
- Interventions
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT05203510
- Locations
- 🇺🇸
Banner University Medical Center (University of Arizona), Phoenix, Arizona, United States
🇺🇸HonorHealth John C. Lincoln Medical Center, Phoenix, Arizona, United States
🇺🇸University of California San Francisco - Fresno, Fresno, California, United States
Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin
- Conditions
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT05060315
- Locations
- 🇺🇸
Syneos Health, Morrisville, North Carolina, United States
Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 792
- Registration Number
- NCT04905693
- Locations
- 🇳🇿
Canterbury Respiratory Research Group, Christchurch, New Zealand
🇺🇸University of Virginia Health Systems, Charlottesville, Virginia, United States
🇲🇽Centro de Prevención y Rehabilitación de Enfermedades Pulmonares Crónicas (CEPREP), Monterrey, Nuevo León, Mexico
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 576
- Registration Number
- NCT04708782
- Locations
- 🇺🇸
Louisville Pulmonary Care,PLLC, Louisville, Kentucky, United States
🇺🇸LSU Health Sciences Center New Orleans, New Orleans, Louisiana, United States
🇺🇸Stony Brook Advanced Specialty Care, Stony Brook, New York, United States
A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT04084678
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇧🇷Centro de Hipertensão Pulmonar, Porto Alegre, Brazil
🇦🇹Ordensklinikum Linz GmbH, Elisabethinen, Linz, Austria
Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
- Conditions
- Interventions
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 51
- Registration Number
- NCT03950739
- Locations
- 🇺🇸
Ascension / St. Vincent's Lung Institute, Jacksonville, Florida, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸University of South Florida Center for Advanced Lung Disease, Tampa, Florida, United States